{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-23-005946","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2023-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.994231+00:00","generated_at":"2026-06-16T16:26:07.626407+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Alzamend Neuro updates investor presentation for April 2023; no material new disclosures","bullets":["Company furnished an updated corporate presentation (Exhibit 99.1) used for investor meetings.","Presentation provides overview of therapeutic drugs for Alzheimer's and other neurodegenerative diseases.","Information furnished under Regulation FD; not deemed filed for SEC or incorporated by reference.","No specific pipeline updates, financial data, or clinical milestones disclosed with this filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-23-005946","json":"https://secwatch.observer/filing/0001214659-23-005946.json","markdown":"https://secwatch.observer/filing/0001214659-23-005946.md","text":"https://secwatch.observer/filing/0001214659-23-005946.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465923005946/0001214659-23-005946-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465923005946/r4252308k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T16:26:07.626407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}